Chelation in metal intoxication.

Flora SJ, Flora SJ, Pachauri V. · 2010

Read Chelation in metal intoxication. by Flora SJ, Flora SJ, Pachauri V. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2922724.txt.

Introduction

Flora and Pachauri updated in 2010 the practice of chelation, using chemical claw molecules to pull toxic metals out of the body. Chelators bind lead, arsenic, mercury, and other metals into complexes the kidneys can excrete. The old workhorse, dimercaprol, saves lives but carries serious side effects, pushing the search for gentler agents.

Water-loving successors such as succimer clear metals through the kidneys well but reach metals hidden inside cells poorly. The review covers newer answers to that weakness: pairing two chelators with different reach, and adding antioxidants to blunt the oxidative damage metals leave behind. Modified ester forms of the standard drugs promise better cell entry. Matching the agent, or the pair, to the metal and the patient is the modern craft.

Catalog record

CREATORFlora SJ, Flora SJ, Pachauri V.
YEAR2010
COLLECTIONPAPERS
FORMATTXT
FILE SIZE127 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC2922724

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Chelation in Metal Intoxication By Swaran JS Flora, Vidhu Pachauri Published in: International Journal of Environmental Research and Public Health DOI: 10.3390/ijerph7072745 ABSTRACT Abstract Chelation therapy is the preferred medical treatment for reducing the toxic effects of metals. Chelating agents are capable of binding to toxic metal ions to form complex structures which are easily excreted from the body removing them from intracellular or extracellular spaces. 2,3-Dimercaprol has long been the mainstay of chelation therapy for lead or arsenic poisoning, however its serious side effects have led researchers to develop less toxic analogues. Hydrophilic chelators like meso-2,3-dimercaptosuccinic acid effectively promote renal metal excretion, but their ability to access intracellular metals is weak. Newer strategies to address these drawbacks like combination therapy (use of structurally different chelating agents) or co-administration of antioxidants have been reported recently. In this review we provide an update of the existing chelating agents and the various strategies available for the treatment of heavy metals and metalloid intoxications. Keywords: chelating agents, combination therapy, oxidative stress, antioxidant, succimer, monoesters, heavy metals INTRODUCTION Metals are an integral part of many structural and functional components in the body, and the critical role of metals in physiological and pathological processes has always been of interest to researchers. Unfolding the latter has inspired newer therapeutic strategies based on alteration of the metal concentrations in specific body organs and/or entire body evolving branches like metallotoxicology and metallopharmacology. The use of metals to restore the normal healthy physiology of the body either by direct administration of essential metals, or by chelating out excess or toxic metals, or using them as carriers for targeted drug delivery, or for tagging biomolecules for diagnostics, are all techniques that may be classified under the general heading of metallo-pharmacology. However, in the present review we will restrict our discussion to chelation therapy which is an important concept and tool for modifying metal concentrations in the body. Chelation has its origin in the Greek word chele that means claw of a lobster, thus depicting the concept of clinging or holding with a strong grip. The term chelate was first applied by Sir Gilbert T. Morgan and H. D. K. Drew in 1920. They suggested the term for the caliper-like groups which function as two associating units and fasten to a central atom so as to produce heterocyclic rings [1]. Metal toxicity may occur due to essential metal overload or exposure to heavy metals from various sources. Most metals are capable of forming covalent bonds with carbon, resulting in metal-organic compounds. Metals and metal compounds interfere with functions of various organ systems like the central nervous system (CNS), the haematopoietic system, liver, kidneys, etc. Diagnostic testing for the presence of heavy metals, and subsequently decreasing the body’s burden of these substances, should be an integral part of the overall treatment regimen for individuals with a metal poisoning symptomatology or a known exposure to these substances. CHELATION: CONCEPT AND CHEMISTRY Although the concept of chelation is based on simple coordination chemistry, evolution of an ideal chelator and chelation therapy that completely removes specific toxic metal from desired site in the body involves an integrated drug design approach. Chelating agents are organic or inorganic compounds capable of binding metal ions to form complex ring-like structure called ‘chelates’. Chelating agents possess “ligand” binding atoms that form either two covalent linkages or one covalent and one co-ordinate or two co-ordinate linkages in the case of bidentate chelates. Mainly atoms like S, N and O function as ligand atoms in the form of chemical groups like –SH, –S-S, –NH2, =NH, –OH, –OPO3H, or >C=O. Bidenate or multidentate ligands form ring structures that include the metal ion and the two-ligand atoms attached to the metal [2] (Figure 1). Many donors act as bidentate ligands. Five-membered chelate rings are specially stable and they are often formed by ligands with YCCY skeltons such as Y-CH2-CH2-Y, Y-CO-CH2-Y etc. where Y is OR, NR2, O, S, NR, etc. There are also examples of inorganic chelate ligands which form five-membered ring with metal ions. Other types of chelating ligands are possible, like EDTA4−, which is a hexadentate ligand. In the simplest case a proton (H+) that can absorb the lone pair of electrons of ligand-binding atom(s) of the chelator may be involved in the coordination complex formation. However, the positive charge on proton remains since there is no loss or gain of electrons in the process. [Figure: Formation of metal ligand complexes using mono, bi and polydentate ligands.] The latter may also be known as the ‘net ionic charge’ of the complex, which plays a crucial role in governing the pharmacokinetic fate and ultimately the toxicological behavior of such complexes in vivo. In the biological environment metal cations viz. Na+, Mg+, Cu+, Cu2+, and Zn2+ and specially the transition metals like Mn, Fe and Co may be involved in such complex formation. Although the stability of such complexes varies, the deciding factors are based on the properties of both the chelating agent and the chelated metal. The stability constant of a complex can be quantitatively expressed in equilibrium equation values, which depend on the atomic structure of the chelated metals. For example, the stability constants for different metals with EDTA are on the scale shown in Table 1, where a metal with higher k constant competes for the chelating agent with a metal of lower stability value and ultimately removes the latter. [Table: EDTA-metal complex stability constants.] However, other variables like the number of heterocyclic rings formed and relative concentration also play a role, that’s why Ca2+, which is readily available in the body fluids, binds preferentially with Na2EDTA in spite of the higher stability constant of Pb. Moreover, in spite of all the known properties desired in an ideal chelator the predictability of the outcome is limited. A chemical entity that qualifies as an ideal chelator in vitro might not prove so in vivo, either due to the toxicity considerations or due to the presence of endogenous substances (hemoglobin, cytochromes, etc.) that can also chelate metal ions and thus offer competition. Further, pH also is an important factor influencing complex formation and stability. Most chelating agents are unstable at low pH, whereas at high pH metals tend to form insoluble hydroxides which are less accessible to chelating agents. This feature becomes significant in pathological conditions leading to acidosis or alkalosis. Optimally effective chelation can be achieved by virtue of some combination of the basic properties of both the metal ions, chelating agents and the resulting metal complex. A chelating agent that will occupy more of the coordination positions of a metal ion will generally (but not always) give a complex of greater stability than otherwise. Similarly, whereas the net ionic charge of the chelator defines its absorption, distribution and ability to reach the metal ion for binding; the net ionic charge of the complex decides its elimination from the specific site and excretion from the body. Thus, it is important that a chelator satisfy criteria that allow it to: (1) transport across physiological barriers into compartments where a toxic metal ion is concentrated, (2) form a stable complex with the metal after removing it from the biological chelator, if required at

Read the complete text